Fresenius Medical Care AG with ticker code (FMS) have now 3 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Underperform’. The target price High/Low ranges between 31.48 and 11.16 calculating the mean target price we have $21.52. Given that the stocks previous close was at $21.54 this is indicating there is a potential downside of -.1%. It’s also worth noting that there is a 50 day moving average of $19.62 and the 200 moving average now moves to $18.01. The total market capitalization for the company now stands at $12,593m. Visit the company website at: https://www.freseniusmedicalcare.com
The potential market cap would be $12,582m based on the market consensus.
Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
The company has a dividend yield of 3.29% with the ex dividend date set at 13-5-2022 (DMY).
Other points of data to note are a P/E ratio of 17.17, revenue per share of 33.07 and a 2.81% return on assets.
